TUESDAY, April 2, 2019 -- In an American Heart Association scientific statement published online March 27 in Circulation, best practices are presented for diagnostic evaluation and management of myocardial infarction in the absence of obstructive coronary artery disease (MINOCA).
Jacqueline E. Tamis-Holland, M.D., from Mount Sinai St. Luke's Hospital in New York City, and colleagues provided an updated definition for MINOCA and developed a framework and algorithms for its diagnostic evaluation and management.
The authors recommend a three-step approach for diagnosis of MINOCA. The initial evaluation involves consideration of the clinical context and exclusion of overt causes for a myocardial infarction that led to diagnosis of acute myocardial infarction but on further review was not the result of an ischemic event. Clinicians should then exclude alternative conditions, including missed obstruction and myocardial injury. Additional testing should be performed to confirm the diagnosis of MINOCA, including cardiac magnetic resonance imaging. Management strategies for MINOCA should include emergency supportive care, a working diagnosis approach for evaluation of patients, cardioprotective therapies, and cause-targeted therapies. The optimal evaluation should determine the specific cause for each patient so that therapies can be targeted.
"Although our proposed algorithm attempts to improve the appropriate identification of patients with MINOCA and the underlying cause, the evaluations outlined here are neither sensitive nor specific, and until more data become available, clinical judgment and individualized care are essential," the authors write.
Several authors disclosed financial ties to the pharmaceutical and medical device industries.
1127-74-8,1,2,3,4-Tetrahydro-benzo[b]azepin-5-one
Read More4038-14-6,(3,4-dimethoxyphenyl)-phenylmethanone
Read More2338-76-3,2-[3-(trifluoromethyl)phenyl]acetonitrile
Read More351-35-9,2-[3-(trifluoromethyl)phenyl]acetic acid
Read More2997-92-4,2,2'-Azobis(2-methylpropionamidine) dihydrochloride
Read More95585-78-7,L-Phenylalanine, 1-methylethyl ester, hydrochloride
Read More20324-87-2,Disodium 7,7'-(carbonyldiimino)bis(4-hydroxynaphthalene-2-sulphonate)
Read More182498-32-4,1-(2-bromophenyl)-3-(2-hydroxy-4-nitrophenyl)urea
Read More1101854-58-3,(4-nitrophenyl) 4-[bis(1,3-benzodioxol-5-yl)-hydroxymethyl]piperidine-1-carboxylate
Read More170565-89-6,N,N-dimethyl-2-oxo-1,3-dihydroindole-5-sulfonamide
Read More1460-59-9,5,6,11,12-tetrahydrodibenzo[1,2-b:1',2'-g][8]annulene
Read More284035-33-2,2-chloro-6-[(2R)-2-hydroxy-3-[(2-methyl-1-naphthalen-2-ylpropan-2-yl)amino]propoxy]benzonitrile
Read More440662-09-9,N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methyl-1-oxo-1,2-dihydroisoquinoline-4-carboxamide
Read More932986-18-0,N-[2-[2-(4-chlorophenyl)-1,3-thiazol-4-yl]ethyl]butanamide
Read More1234015-52-1,5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile
Read More1651890-44-6,3'-Methyl-3''-[(1E)-2-phenylethenyl]-3,2':5',2'':5'',3'''-quaterpyridine
Read More1469924-27-3,3-[4'-(Dimethylamino)-3-biphenylyl]-1,1-dimethylure
Read More3897-94-7,8-Methoxy-N,N-dipropyl-1,2,3,4-tetrahydro-2-naphthalenamine
Read More1202759-32-7,4-{4-[(4-{[3-(Acryloylamino)phenyl]amino}-5-fluoro-2-pyrimidinyl) amino]phenoxy}-N-methyl-2-pyridinecarboxamide
Read More71145-03-4,1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-pyridine-5-carboxylic acid methyl ester
Read More500579-04-4,2-[[3-[[2-(dimethylamino)phenyl]methyl]-2-pyridin-4-yl-1,3-diazinan-1-yl]methyl]-N,N-dimethylaniline
Read More1443437-74-8,N-(4-chlorophenyl)-1-(3-(furan-2-yl)benzoyl)piperidine-3-carboxamide
Read More1125-29-7 1,3,5-Trimethyl-1H-pyrazole-4-carboxylic acid
Read More23362-56-3 [2-(aminocarbonyl)phenyl]acetic acid
Read More103788-65-4 2-(5-Methyl-2-phenyl-1,3-oxazol-4-yl)ethan-1-ol
Read More120503-69-7 2-Amino-6-cyclopropylamino-9H-purine
Read More